Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?

In 2015, the launch of two new potent drugs to lower LDL-cholesterol (LDL-c) , Repatha (Amgen) and Praluent (Sanofi/Regeneron), sent shivers down the spines of payers. These drugs, the first of a class of new drugs known as PCSK9 inhibitors, were extremely effective.